Personally I've always felt that ADAPT was the main driver for AHZ.
I've ignored the vaccine biz as the chances of success are slim.
On ADAPT alone I see AHZ moving towards $1 within 4 years.
it is the gold standard soft tissue patch, it has multiple potential applications within the human body.
Yes competition could appear but I haven't seen any yet. They raised capital to build their salesforce and capitalise on this opportunity. The numbers should start to reflect this in the next Qrtly.
Personally I've always felt that ADAPT was the main driver for...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |